Zetagen Therapeutics, a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced the successful closure of its Series B1 financing round of $12,908,000. The round was 100% oversubscribed, reflecting strong investor confidence in the company's proprietary Zeta Platform and its potential to transform breast cancer care.

The funding round closed with strong demand from private investors-led by JSTAR Capital Investments-demonstrating deep confidence in our clinical efficacy.

Zetagen has three novel drugs in development with the Zeta Platform, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit www.zetagen.com. The entire Zeta platform is designed for intratumoral administration to reduce off-target toxicity, utilizing proprietary carriers-some incorporating our New Molecular Entity. The USPTO has granted Zetagen Composition-of-Matter patents and claims for all three therapeutics.